Sutro Biopharma (STRO) Net Equity Issued and Repurchased (2019 - 2024)
Sutro Biopharma (STRO) posted Net Equity Issued and Repurchased of -$50.0 million for Q2 2024, down 134.92% sequentially from $143.2 million in Q4 2020.
Powered by 
Analysis
Sutro Biopharma (STRO) Net Equity Issued and Repurchased (2019 - 2024) Analysis & Trends
Sutro Biopharma has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at -$50.0 million in Q2 2024.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to -$50.0 million in Q2 2024, while the trailing twelve-month figure through Sep 2025 was -$50.0 million (down 145.47% YoY) and the FY2024 annual result came in at $25.0 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased retreated to -$50.0 million in Q2 2024 per STRO's latest filing, from $143.2 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $143.2 million in Q4 2020 and troughed at -$50.0 million in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | - |
| 10 | Sutro Biopharma | 332.26 Mn | 167.91 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -50.00 Mn |
| Dec 31, 2020 | 143.17 Mn |
| Sep 30, 2020 | 16.80 Mn |
| Dec 31, 2019 | -327,000.00 |